Ascelia Pharma AB (publ) (ACE ST) stock market data APIs
kr0.6329
0(0%)
as of September 11, 2026
Try our APIs with
free plan!
Ascelia Pharma AB (publ) Financial Data Overview
Price chart is built with
Anychart
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.
Prev. Close
0.6329
Open
0.6364
High
0.6683
Low
0.6181
52 wk Range
0.455-3.98
Market Cap
85 062 K
Shares Outstanding
134 M
EPS
-0.13
Beta
0.854
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Ascelia Pharma AB (publ) data using free add-ons & libraries
Get Ascelia Pharma AB (publ) Fundamental Data
Ascelia Pharma AB (publ) Fundamental data includes:
- Net Revenue:
- EBITDA: -59 412 500
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Ascelia Pharma AB (publ) Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-02-05
- EPS/Forecast: 0.5
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ascelia Pharma AB (publ) News
New
Ascelia Pharma Completes FDA Type A Meeting on Orviglance NDA
MALMÖ, SE / ACCESS Newswire / September 10, 2026 / Ascelia Pharma (STO:ACE) completed the previously scheduled Type A meeting with the U.S. Food and Drug Administration (FDA) on September 9, 2026, re...
Trade Alert: The Director Of Ascelia Pharma AB (publ) (STO:ACE), Niels Mengel, Has Just Spent kr204k Buying 42% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the Ascelia Pharma AB (publ) (STO:ACE) Director, Niels Mengel, recently bought kr204k worth of stock, for kr20.38 per share. While ...
We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenu...
Get Ascelia Pharma AB (publ) fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
